Neoadjuvant immunotherapy was associated with better survival and pathologic downstaging in muscle-invasive bladder cancer in comparison to no neoadjuvant therapy, and was comparable to chemotherapy. Immunotherapy may be a viable bladder cancer treatment before cystectomy.